Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Multiple Sclerosis: HELP
Articles by Lucas Paula-Ramos
Based on 1 article published since 2009
(Why 1 article?)
||||

Between 2009 and 2019, Lucas Paula-Ramos wrote the following article about Multiple Sclerosis.
 
+ Citations + Abstracts
1 Review Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials. 2017

da Rovare, Victoria P / Magalhães, Gabriel P A / Jardini, Guilherme D A / Beraldo, Matheus L / Gameiro, Mariel O / Agarwal, Arnav / Luvizutto, Gustavo José / Paula-Ramos, Lucas / Camargo, Samira Esteves Afonso / de Oliveira, Luciane Dias / Bazan, Rodrigo / El Dib, Regina. ·São Paulo State University (Unesp), Botucatu Medical School, São Paulo, Brazil. Electronic address: victoriarovare@gmail.com. · São Paulo State University (Unesp), Botucatu Medical School, São Paulo, Brazil. Electronic address: beelz.magalhaes@gmail.com. · São Paulo State University (Unesp), Botucatu Medical School, São Paulo, Brazil. Electronic address: guilhermejardini@gmail.com. · São Paulo State University (Unesp), Botucatu Medical School, São Paulo, Brazil. Electronic address: beraldoa@hotmail.com. · São Paulo State University (Unesp), Botucatu Medical School, São Paulo, Brazil. Electronic address: marielorsi@gmail.com. · Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: arnav.mcmaster@gmail.com. · São Paulo State University (Unesp), Department of Neurology, Botucatu Medical School, Brazil. Electronic address: gustavo.luvizutto@uftm.edu.br. · São Paulo State University (Unesp), Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo, Brazil. Electronic address: lucas93paula@hotmail.com.br. · São Paulo State University (Unesp), Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo, Brazil. Electronic address: samira@ict.unesp.br. · São Paulo State University (Unesp), Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo, Brazil. Electronic address: luciane@ict.unesp.br. · São Paulo State University (Unesp), Department of Neurology, Botucatu Medical School, Brazil. Electronic address: bazan.r@terra.com.br. · São Paulo State University (Unesp), Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo, Brazil; São Paulo State University (Unesp), Department of Anesthesiology, São Paulo, Brazil; McMaster Institute of Urology, McMaster University, St. Joseph's Healthcare, Hamilton, Canada. Electronic address: eldib@fmb.unesp.br. ·Complement Ther Med · Pubmed #28917371.

ABSTRACT: OBJECTIVES: Spasticity remains highly prevalent in patients with spinal cord injury and multiple sclerosis. To summarize the effects of cannabinoids compared with usual care, placebo for spasticity due to multiple sclerosis (MS) or paraplegia. METHODS: Searches of MEDLINE, EMBASE, CENTRAL and LILACS to March 2017 were performed to identify randomized controlled trials. The primary outcomes were spasticity and spasm frequency. The criteria were any patient with MS and spasticity affecting upper or lower limbs or both, and that had a confirmed diagnosis of MS based on validated criteria, or however defined by the authors of the included studies. RESULTS: 16 trials including 2597 patients were eligible. Moderate-certainty evidence suggested a non-statistically significant decrease in spasticity (standardized mean difference (SMD) 0.36 [confidential interval (CI) 95% -0.17 to 0.88; p=0.18; I2=88%]), and spasm frequency (SMD 0.04 [CI 95% -0.15 to 0.22]). There was an increase in adverse events such as dizziness (risk ratio (RR) 3.45 [CI 95% 2.71-4.4; p=0.20; I2=23%]), somnolence (RR 2.9 [CI 95% 1.98-4.23; p=0.77; I2=0%]), and nausea (RR 2.25 [CI 95% 1.62-3.13; p=0.83; I2=0%]). CONCLUSIONS: There is moderate certainty evidence regarding the impact of cannabinoids in spasticity (average 0.36 more spasticity; 0.17 fewer to 0.88 more) due to multiple sclerosis or paraplegia, and in adverse events such as dizziness (419 more dizziness/1000 over 19 weeks), somnolence (127 more somnolence/1000 over 19 weeks), and nausea (125 more somnolence/1000 over 19 weeks).